Mitsubishi Tanabe Pharma America Presents Data on Impact of ALS Symptoms on Patients Ability to Independently Conduct Daily Activities
Analysis Shared at 2021 Muscular Dystrophy Association Annual Clinical & Scientific Conference
News provided by
Share this article
Share this article
JERSEY CITY, N.J., March 17, 2021 /PRNewswire/ Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced findings from a new analysis evaluating the impact of symptom progression on the ability of people with amyotrophic lateral sclerosis (ALS) to independently conduct activities of daily living (ADLs). The findings were shared during a virtual presentation at the 2021 Muscular Dystrophy Association Clinical & Scientific Conference. As part of our commitment to patients and their caregivers, MTPA wanted to explore how different disease symptom progression impacts an ALS patients ability to independently perform daily activities, such as cleaning, housework, cooking and traveling outside
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Libervant™ (diazepam) Buccal Film New Drug Application (NDA) resubmission expected end of second quarter 2021
Epinephrine program and development strategy to be highlighted at a virtual investor event to be held at 9:00 a.m. ET on March 25, 2021
Entered U.S. licensing and supply agreement for Riluzole Oral Film for treatment of ALS with Mitsubishi Tanabe Pharma America
Sympazan
® (clobazam) continues to meet key performance metrics
Management to host conference call and webcast at 8:00 a.m. ET on March 10, 2021
WARREN, N.J., March 09, 2021 (GLOBE NEWSWIRE) Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Mitsubishi Tanabe Pharma America Celebrates Five Years of Dedication to the ALS Community in the U.S.
February 8, 2021 GMT
MTPA Logo (PRNewsfoto/Mitsubishi Tanabe Pharma Americ)
JERSEY CITY, N.J., Feb. 8, 2021 /PRNewswire/ Mitsubishi Tanabe Pharma America, Inc. (MTPA) today celebrated its five-year anniversary of being established in the United States in 2016. MTPA has followed an unwavering patient-first philosophy focused on advancing innovative treatments for people facing serious and life-threatening diseases, including amyotrophic lateral sclerosis (ALS).
“Having personally been a part of the MTPA journey from the beginning, I am humbled by what we have achieved as one team, with one mission: helping patients,” said Atsushi Fujimoto, President, MTPA. “We have accomplished many things in the first five years working together to serve the ALS community, and we look forward to s